Georgetown University: Pancreatic Neoplasms trials

The registry lists 12 Pancreatic Neoplasms studies with Georgetown University as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 3Phase 2 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT06423326Phase 2
• Maintenance Dovitinib for Colorectal and Pancreas CancerTerminatedNCT01888965Phase 2Results posted
• ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic CancerCompletedNCT01489865Phase 1/2Results posted
• Lapatinib and Capecitabine for Second Line Treatment of Pancreas CancerTerminatedNCT00881621Phase 2Results posted
• Study of Pemetrexed for Second-Line Pancreas CancerTerminatedNCT00864513Phase 2Results posted
• Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal AdenocarcinomaWithdrawnNCT06017323Phase 1
• Proglumide and Chemotherapy for Metastatic Pancreatic CancerActive, not recruitingNCT05827055Phase 2
• Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic CancerWithdrawnNCT02967770Phase 2
• Study of Gemcitabine and Abraxane for Pancreas CancerTerminatedNCT02242409Phase 2
• Molecularly Tailored Therapy for Pancreas CancerCompletedNCT01888978Phase 2
• A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic CancerCompletedNCT01051284Phase 1
• Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced TumorsCompletedNCT00003125Phase 2